Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK8AQP)

• Drug Name: Sirukumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous lupus erythematosus	EB5Z	Phase 3	[1]
Giant cell arteritis	4A44.2	Phase 3	[2]
Rheumatoid arthritis	FA20	Phase 3	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Major depressive disorder	6A70.3	Phase 2	[5]

• Cross-matching ID: TTD Drug ID: DMK8AQP

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siltuximab	DMGEATB	Anemia	3A00-3A9Z	Approved	[8]
Olokizumab	DM4Z9QI	Rheumatoid arthritis	FA20	Phase 3	[9]
Ziltivekimab	DME841B	Heart failure	BD10-BD13	Phase 3	[10]
RG6179	DMO1VP9	uveitic macular edema	9B78	Phase 3	[11]
PF-04236921	DM826SW	Crohn disease	DD70	Phase 2	[2]
Clazakizumab	DM6ZOUV	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[2]
CDP-6038	DM3YB2C	Rheumatoid arthritis	FA20	Phase 2	[12]
ALD-518	DMPWSBL	Psoriatic arthritis	FA21	Phase 2	[12]
YSIL6	DM0K8U7	Crohn disease	DD70	Phase 2	[13]
Gerilimzumab	DMA9UX2	Rheumatoid arthritis	FA20	Phase 1	[2]

Drug(s) Targeting Interleukin 6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tocilizumab	DM7J6OR	Giant cell arteritis	4A44.2	Approved	[14]
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[15]
SAR153191	DMXAO4J	Ankylosing spondylitis	FA92.0	Phase 3	[16]
SA-237	DM7F2VG	Encephalopathy	8E47	Phase 3	[17]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[18]
ALX-0061	DMO1VHC	Autoimmune diabetes	5A10	Phase 2	[19]
SBP-002	DM9F7R0	Melanoma	2C30	Terminated	[15]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[20]
FM-101	DMXK6EI	Multiple myeloma	2A83	Investigative	[6]
Sant7	DM9CV4P	Multiple myeloma	2A83	Investigative	[21]

Drug(s) Targeting HUMAN interleukin 6 (IL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Siltuximab	DMGEATB	Anemia	3A00-3A9Z	Approved	[22]
Olokizumab	DM4Z9QI	Rheumatoid arthritis	FA20	Phase 3	[23]
Clazakizumab	DM6ZOUV	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2 Trial	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 6 receptor (IL6R)	TT0E5SK	IL6RA_HUMAN; IL6RB_HUMAN	Not Available	[6]
Interleukin-6 (IL6)	TTT1V78	IL6_HUMAN	Inhibitor	[2]
HUMAN interleukin 6 (IL6)	TTJH4Y5	IL6_HUMAN	Inhibitor	[7]

References

• [1] ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT01689532) A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT04380961) A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19. U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
• [7] Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.
• [8] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [9] Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
• [10] IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 May 29;397(10289):2060-2069.
• [11] Clinical pipeline report, company report or official report of Roche
• [12] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)
• [14] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [17] IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
• [18] Clinical pipeline report, company report or official report of Ablynx.
• [19] The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
• [20] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [21] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [22] Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3.
• [23] Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.
• [24] Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452.